跳轉至內容
Merck
全部照片(1)

重要文件

1448923

USP

莫匹罗星锂

United States Pharmacopeia (USP) Reference Standard

同義詞:

9-((E)-4-{(2S,3R,4R,5S)-3,4-二羟基-5-[(2S,3S)-3-((1S,2S)-2-羟基-1-甲基-丙基)环氧乙烷基甲基]四氢吡喃-2-基}-3-甲基-丁-2-烯酰氧基)壬酸 锂盐, 假单胞菌酸A 锂盐

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C26H43LiO9
CAS號碼:
分子量::
506.56
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

mupirocin

製造商/商標名

USP

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

[Li+].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)[C@H](O)[C@@H]2O

InChI

1S/C26H44O9.Li/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27;/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29);/q;+1/p-1/b16-13+;/t17-,18-,19-,20-,21-,24+,25-,26-;/m0./s1

InChI 密鑰

XFIKMPRBSORKQP-JATHGWPISA-M

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Mupirocin lithium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Mupirocin
  • Mupirocin Calcium
  • Mupirocin Cream
  • Mupirocin Nasal Ointment
  • Mupirocin Ointment

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 1

1 of 1

Erysipelas as a superinfection of an oral lymphangioma.
Iria Neri et al.
The Journal of pediatrics, 165(1), 205-205 (2014-05-06)
Christophe Camus et al.
Critical care medicine, 42(5), 1121-1130 (2013-12-25)
In a multicenter, placebo-controlled, randomized, double-blind trial, we showed that acquired infections in intubated patients were reduced by the combination of topical polymyxin plus tobramycin and nasal mupirocin plus chlorhexidine body wash. Because intubated patients are particularly at risk for

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務